Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERMNASDAQ:OGINASDAQ:OKYONASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.14+2.0%$7.04$3.54▼$8.25$166.36M0.8788,052 shs1.60 million shsOGIOrganigram Global$1.35-3.6%$1.28$0.85▼$3.02$180.82M1.37657,385 shs540,412 shsOKYOOKYO Pharma$2.45+1.2%$1.84$0.81▼$4.34$82.91M-0.27147,890 shs40,321 shsSCPHscPharmaceuticals$3.87-2.8%$3.30$1.94▼$5.65$204.31M0.36370,879 shs688,056 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical0.00%+9.68%-11.41%+21.02%+26.60%OGIOrganigram Global0.00%+4.65%+2.14%+33.66%-12.34%OKYOOKYO Pharma0.00%+3.38%+32.70%+92.91%+105.88%SCPHscPharmaceuticals0.00%+0.78%+9.32%+47.15%-11.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDERMJourney Medical2.1259 of 5 stars3.51.00.00.02.41.70.6OGIOrganigram Global1.2225 of 5 stars0.01.00.00.03.30.02.5OKYOOKYO Pharma2.5983 of 5 stars3.53.00.00.03.31.70.0SCPHscPharmaceuticals4.5741 of 5 stars3.54.00.04.23.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 3.00Buy$9.5033.05% UpsideOGIOrganigram Global 3.00BuyN/AN/AOKYOOKYO Pharma 3.00Buy$7.00185.71% UpsideSCPHscPharmaceuticals 3.00Buy$14.00261.76% UpsideCurrent Analyst Ratings BreakdownLatest OKYO, DERM, OGI, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.13M2.96N/AN/A$0.91 per share7.85OGIOrganigram Global$117.47M1.54N/AN/A$2.07 per share0.65OKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/ASCPHscPharmaceuticals$41.98M4.87N/AN/A$0.27 per share14.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)OGIOrganigram Global-$33.39M$0.1013.50N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)OKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)SCPHscPharmaceuticals-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)Latest OKYO, DERM, OGI, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.071.341.03OGIOrganigram GlobalN/A3.421.90OKYOOKYO PharmaN/A0.28N/ASCPHscPharmaceuticals3.865.484.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%OGIOrganigram Global34.63%OKYOOKYO Pharma2.97%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%OGIOrganigram Global0.09%OKYOOKYO Pharma40.46%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9023.30 million19.80 millionN/AOGIOrganigram Global860133.94 million133.82 millionOptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionableSCPHscPharmaceuticals3052.79 million50.27 millionOptionableOKYO, DERM, OGI, and SCPH HeadlinesRecent News About These CompaniesWith 42% stake, scPharmaceuticals Inc. (NASDAQ:SCPH) seems to have captured institutional investors' interestJune 12, 2025 | finance.yahoo.comNuveen Asset Management LLC Has $320,000 Position in scPharmaceuticals Inc. (NASDAQ:SCPH)June 6, 2025 | marketbeat.comscPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025May 22, 2025 | seekingalpha.comscPharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 16, 2025 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectoryMay 16, 2025 | msn.comQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comQ1 2025 scPharmaceuticals Inc Earnings CallMay 16, 2025 | finance.yahoo.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%May 16, 2025 | aaii.comAWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 18.30%May 16, 2025 | aaii.comAscPharmaceuticals Inc. (SCPH) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue EstimatesMay 14, 2025 | zacks.comscPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | globenewswire.comInsights Ahead: scPharmaceuticals's Quarterly EarningsMay 13, 2025 | benzinga.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Up 5.24%May 7, 2025 | aaii.comAscPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025May 7, 2025 | globenewswire.comWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Down 5.85%May 6, 2025 | aaii.comAscPharmaceuticals Announces Participation in Three Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comscPharmaceuticals Stock Price, Quotes and ForecastsApril 25, 2025 | benzinga.comAnalysts Are Bullish on These Healthcare Stocks: scPharmaceuticals (SCPH), Sarepta Therapeutics (SRPT)April 23, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernBy Leo Miller | June 2, 2025View Analysts Are Bullish on Marvell Stock Despite Amazon Deal ConcernUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesSoFi Stock’s Next Test: Can It Justify Its Premium Valuation?By Chris Markoch | June 13, 2025View SoFi Stock’s Next Test: Can It Justify Its Premium Valuation?Wall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPEGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractOKYO, DERM, OGI, and SCPH Company DescriptionsJourney Medical NASDAQ:DERM$7.14 +0.14 (+2.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$6.62 -0.52 (-7.28%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Organigram Global NASDAQ:OGI$1.35 -0.05 (-3.57%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.02 +1.67 (+123.70%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.OKYO Pharma NASDAQ:OKYO$2.45 +0.03 (+1.24%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$4.34 +1.89 (+77.14%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.scPharmaceuticals NASDAQ:SCPH$3.87 -0.11 (-2.76%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$4.20 +0.33 (+8.53%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
